Transplantation - Clinical Care Options

Improving Long-term Outcomes in Renal Transplant Recipients: Balancing Immunosuppression and Toxicity

Expert faculty led by Flavio Vincenti, MD, and Donald Hricik, MD, present data on using maintenance immunosuppression regimens to best prolong graft survival and at the same time manage toxicity related to the regimens.

Source: A Master Class in Improving Long-term Outcomes in Renal Transplant Recipients: Balancing Immunosuppression and Toxicity

Date Posted: 6/6/2012
Highlights From the American Transplant Congress 2011

In this downloadable slideset, Seth J. Karp, MD, and Flavio Vincenti, MD, provide commentary and analysis on key studies in transplantation from the 2011 American Transplant Congress.

Source: American Transplant Congress 2011

Faculty: Seth J. Karp MD, Flavio Vincenti MD

Released: 6/15/2011
CCO Slideset: Highlights From the American Transplant Congress 2011

In this downloadable slideset, Seth J. Karp, MD, and Flavio Vincenti, MD, review key studies in transplantation from the 2011 American Transplant Congress.

Source: American Transplant Congress 2011

Date Posted: 5/19/2011
Alefacept-Based Regimens Significantly Reduce T-Cell Memory Subsets but Associated With Increased Rejection Rates vs Control Regimen in Kidney Transplant Recipients

Patients in alefacept arms more likely to not complete at least 6 months of therapy compared with control arm; higher rates of discontinuation largely driven by adverse events and graft rejection.

Source: American Transplant Congress 2011

Date Posted: 5/5/2011
Total Lymphoid Irradiation, Antithymocyte Globulin, and Donor Hematopoietic Cell Infusion Safely and Successfully Induces Tolerance After HLA-Matched Kidney Transplant

Posttransplant conditioning regimen of total lymphoid irradiation, antithymocyte globulin, and donor hematopoietic cell infusion promoted safe development of mixed chimerism and tolerance in majority of HLA-matched kidney transplant recipients.

Source: American Transplant Congress 2011

Date Posted: 5/5/2011
HIV-Related Factors Such as HIV-1 RNA and CD4+ Cell Count Not Associated With Survival After Kidney or Liver Transplantation in HIV-Infected Individuals

In this prospective cohort study, the strongest factors associated with survival among kidney recipients were hepatitis C virus coinfection and age, whereas dual organ transplantation, pretransplantation BMI, and donor age demonstrated the strongest survival associations in liver transplant recipients.

Source: American Transplant Congress 2011

Date Posted: 5/5/2011
Proteasome Inhibitor–Based Therapy Provides Effective Reversal of Antibody-Mediated Rejection in Kidney Transplantation

Rates of histologic improvement, graft survival, and patient survival all high with bortezomib therapy with acceptable toxicity profile.

Source: American Transplant Congress 2011

Date Posted: 5/5/2011
BENEFIT and BENEFIT-EXT: Pooled Safety Data Through 3 Years Reveal No New Safety Signals Associated With Belatacept Costimulation Blockade

The risk of PTLD with belatacept was highest during the first 18 months of treatment, and most cases occurred in EBV-negative patients.

Source: American Transplant Congress 2011

Date Posted: 5/4/2011
Preliminary Results Suggest That Alemtuzumab Induction Followed by Belatacept and Sirolimus Maintenance Prevents Renal Allograft Rejection and Alloantibody Formation

This novel calcineurin inhibitor– and steroid-free regimen appears to have potential, although with the potential for asymptomatic BK viremia.

Source: American Transplant Congress 2011

Date Posted: 5/4/2011
Favorable Graft and Patient Survival Among HIV-Infected Patients Who Received Kidney Transplant Regardless of Use of NIH Study Protocol or Center Experience

Excellent graft and patient survival observed among HIV-infected patients who received kidney transplant for ESRD, regardless of center experience with HIV-positive ESRD transplant patients or enrollment according to NIH study protocol.

Source: American Transplant Congress 2011

Date Posted: 5/4/2011

Other Sites

Educational Formats

User Resources

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Latest Content

Improving Long-term Outcomes in Renal Transplant Recipients: Balancing Immunosuppression and Toxicity

Highlights From the American Transplant Congress 2011

CCO Slideset: Highlights From the American Transplant Congress 2011

Alefacept-Based Regimens Significantly Reduce T-Cell Memory Subsets but Associated With Increased Rejection Rates vs Control Regimen in Kidney Transplant Recipients

Total Lymphoid Irradiation, Antithymocyte Globulin, and Donor Hematopoietic Cell Infusion Safely and Successfully Induces Tolerance After HLA-Matched Kidney Transplant

HIV-Related Factors Such as HIV-1 RNA and CD4+ Cell Count Not Associated With Survival After Kidney or Liver Transplantation in HIV-Infected Individuals

Proteasome Inhibitor–Based Therapy Provides Effective Reversal of Antibody-Mediated Rejection in Kidney Transplantation

BENEFIT and BENEFIT-EXT: Pooled Safety Data Through 3 Years Reveal No New Safety Signals Associated With Belatacept Costimulation Blockade

Preliminary Results Suggest That Alemtuzumab Induction Followed by Belatacept and Sirolimus Maintenance Prevents Renal Allograft Rejection and Alloantibody Formation

Favorable Graft and Patient Survival Among HIV-Infected Patients Who Received Kidney Transplant Regardless of Use of NIH Study Protocol or Center Experience

Filter Content By

CCO Live Meetings